Post-Transplant Outcomes in High-Risk Compared With Non-High-Risk Multiple Myeloma: A CIBMTR Analysis

In conclusion, we show HRM patients achieve similar day 100 post-transplant responses compared with non-HRM patients, but these responses are not sustained. Post-transplant therapy appeared to improve the poor outcomes of HRM.

 Biol Blood Marrow Transplant

click me